drugset / Trial / NCT04682964

Bacteriophage Therapy in Tonsillitis

NCT04682964 ↗

NaSingle-groupOpen-labelSupportive care

Summary

The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa. A total of 5 ml of PCL was inhaled for 10 minutes every 5 days. The drug causes the lysis of certain bacteria, including staphylococcus, enterococcus, streptococcus, enteropathogenic E. coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Klebsiella oxytoca. The choice of this drug was based on bacteriological studies.

Timeline

Start
2020-10-02
Primary completion
2025-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject liquid piobacteriophage complex Unknown 5 ml Inhaled

Indications